Reporters learnt from the China Food and Drug Administration (CFDA) that the government agency has approved Ginsenoside CK of Zhejiang Hisun Pharmaceutical Co., Ltd. (SHSE: 600267) to enter clinical test phase.
Ginsenoside CK has pharmacological activity that can retrain cancer cell transfer, hence is a prospective chemical and worthy of being developed as a new drug.
Source:
http://www.sinocast.com/readbeatarticle.do?id=99261
